Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct:219:108550.
doi: 10.1016/j.clim.2020.108550. Epub 2020 Jul 31.

Critical COVID-19 disease, homeostasis, and the "surprise" of effective glucocorticoid therapy

George P Chrousos  1 , G Umberto Meduri  2
Affiliations

Critical COVID-19 disease, homeostasis, and the "surprise" of effective glucocorticoid therapy

George P Chrousos et al. Clin Immunol. 2020 Oct.
No abstract available

PubMed Disclaimer

Figures

Fig 1
Fig 1
In severe/critical COVID-19 disease, there is activation of the “immune and inflammatory reaction” and “the stress response”, two important homeostatic systems that work together to achieve survival. The former consists of 4 programs that unfold in tandem with the stress program: “sickness behavior”, the “acute phase reaction”, which includes hemostasis, “the pain and fatigue afferent system”, as well as the “tissue reaction”. The latter consists of the “arousal/autonomic nervous system” and “the hypothalamic-pituitary-adrenal (HPA) axis”, which act synergistically and/or antithetically to the immune and inflammatory reaction in a highly complex, stochastic way.
See this image and copyright information in PMC

References

    1. Zhang W., Zhao Y., Zhang F., Wang Q., Li T., Liu Z., Wang J., Qin Y., Zhang X., Yan X., Zeng X., Zhang S. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin. Immunol. 2020 May;214 doi: 10.1016/j.clim.2020.108393. (Epub 2020 Mar 25. PMID: 32222466; PMCID: PMC7102614) - DOI - PMC - PubMed
    1. Han Y., Jiang M., Xia D., He L., Lv X., Liao X., Meng J. COVID-19 in a patient with long-term use of glucocorticoids: a study of a familial cluster. Clin Immunol. 2020 May;214 doi: 10.1016/j.clim.2020.108413. 108413. Epub 2020 Apr 8. PMID: 32276139; PMCID: PMC7139268. - DOI - PMC - PubMed
    1. Keller M.J., Kitsis E.A., Arora S., Chen J.-T., Agarwal S., Ross M.J., Tomer Y. Southern W effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19. J Hosp Med. 2020 doi: 10.12788/jhm.3497. Published Online First July 22. - DOI - PMC - PubMed
    1. Chrousos G.P., Trevor A.J. Chapter 39. Adrenocorticosteroids and adrenocortical antagonists. In: Katzung B., Masters S.B., editors. Basic and Clinical Pharmacology. 13th edition. Lange, McGraw-Hill; New York, New York: 2015. pp. 680–695.
    1. Meduri G.U., Chrousos G.P. General adaptation in critical illness: glucocorticoid receptor-alpha, master regulator of homeostatic corrections. Front. Endocrinol. 2020;11(1 April) www.frontiersin.org Article 161. - PMC - PubMed

MeSH terms